newsfilter
← Latest News
PR Newswire·

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model...